Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/47390
Title: | Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group | Authors: | Gürbüz, Mustafa Akkuş, Erman Sakin Abdullah Urvay, Semiha Demiray, Atike Gökçen Şahin, Süleyman Şakalar, Teoman Erol, Cihan Şendur, Mehmet Ali Nahit Şahin, Ahmet Bilgehan Çubukçu, Erdem Güven, Deniz Can Kılıçkap, Saadettin Ergün, Yakup Uncu, Doğan Turhal, Nazım Serdar Üskent, Necdet Çınkır, Havva Yeşil Demir, Atakan Acar, Ramazan Karadurmuş, Nuri Türker, Sema Altınbaş, Mustafa Karaoğlan, Mert Şenler, Filiz Çay |
Keywords: | Chemotherapy Gastric cancer HER2 Maintenance Trastuzumab capecitabine cisplatin epidermal growth factor receptor 2 fluorouracil folinic acid oxaliplatin trastuzumab antineoplastic agent capecitabine epidermal growth factor receptor 2 trastuzumab adjuvant chemoradiotherapy adult aged anemia Article bone metastasis cardiotoxicity clinical article colorectal adenocarcinoma diarrhea drug efficacy drug safety fatigue febrile neutropenia female fever hand foot syndrome human infusion related reaction liver metastasis lung metastasis lymph node metastasis maintenance therapy male multiple cycle treatment nausea neoadjuvant chemotherapy neutropenia observational study overall survival peritoneum metastasis progression free survival rash retrospective study stomach adenocarcinoma thrombocytopenia Turkey (republic) vomiting clinical trial multicenter study pathology stomach tumor Antineoplastic Combined Chemotherapy Protocols Capecitabine Humans Receptor, ErbB-2 Retrospective Studies Stomach Neoplasms Trastuzumab |
Publisher: | Springer | Abstract: | Purpose: In the ToGA trial for HER2-positive advanced gastric cancer, cisplatin plus fluoropyrimidine was given for 6 cycles; trastuzumab was given until disease progression. However, there is a lack of real-life data about trastuzumab maintenance after 6 cycle chemotherapy. This study aims to present real-life data of trastuzumab ± capecitabine maintenance after 6 cycles of platinum, fluoropyrimidine, and trastuzumab in non-progressive patients. Methods: This is a retrospective multicenter study of the Turkish Oncology Group. A total of 35 HER2-positive, inoperable locally advanced, recurrent, or metastatic gastric adenocarcinoma patients being non-progressive at the end of 6 cycle chemotherapy and being given trastuzumab ± capecitabine as maintenance treatment were included from sixteen oncology centers. Baseline characteristics, objective tumor responses, progression free and overall survival data, and toxicities were determined. Results: About 68% of the patients were given CF, and 32% were given FOLFOX with trastuzumab as the first-line treatment. The best response in 6 cycle chemotherapy was complete 8 (22%), partial 24 (68%), and stable disease 3 (8%). All patients had trastuzumab maintenance (median cycle 13; range 7–51), and 49% of the patients had capecitabine with trastuzumab (median capecitabine cycle 6; range 2–30). The median PFS of the patients was 12.0 months (95% CI 10.3–13.7), and median OS was 17.4 months (95% CI 15.2–19.5). There were 2 patients with grade 1 cardiotoxicity. Conclusion: Trastuzumab maintenance ± capecitabine after 6 cycles of trastuzumab plus combined chemotherapy treatment revealed efficacy and safety in non-progressive HER2-positive advanced gastric cancer. © 2021, Springer Science+Business Media, LLC, part of Springer Nature. | URI: | https://doi.org/10.1007/s12029-021-00594-1 https://hdl.handle.net/11499/47390 |
ISSN: | 1941-6628 |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu |
Show full item record
CORE Recommender
SCOPUSTM
Citations
4
checked on Oct 13, 2024
Page view(s)
48
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.